心脏纤维化
心肌纤维化
医学
心功能曲线
封锁
心肌梗塞
纤维化
下调和上调
单克隆抗体
心力衰竭
心脏病学
调解人
活性氧
抗体
内科学
药物输送
心室重构
成纤维细胞
治疗效果
药理学
病态的
相伴的
细胞凋亡
癌症研究
病理
炎症
作者
Ting You,Yong Zhang,Haotao Su,Na Wang,Xinkui Zhang,Sainiwaier Anwaier,Xiang Lian Long,Linjiang Han,Yeting Wu,Jialiang Liang,Yanzhen Yang,Chenghao Yu,Zerui Chen,Jian Liu,Tucheng Sun,Huanlei Huang,Shuoji Zhu,Nanbo Liu,Ping Zhu,Jimei Chen
标识
DOI:10.1016/j.bioactmat.2026.01.041
摘要
Myocardial fibrosis, driven by fibroblast activation following myocardial infarction (MI), represents a significant pathological process contributing to heart failure progression. Interleukin-11 (IL-11) is recognized as a key mediator in fibrotic pathologies across multiple organs, including the heart. This study demonstrates consistent and specific upregulation of IL-11 expression in a mouse MI model. A single intrapericardial injection of the IL-11-blocking antibody hIL-11 MAB resulted in a modest attenuation of post-MI fibrosis. Subsequently, encapsulation of hIL-11 MAB within reactive oxygen species (ROS)-sensitive hydrogels significantly prolonged drug retention at the injury site, leading to markedly improved therapeutic efficacy. Hydrogel-delivered hIL-11 MAB effectively preserved cardiac structure and function by reducing scar fibrosis, specifically decreasing scar thickness and marginal zone area. IL-11 blockade mediated reduced collagen deposition and enhanced left ventricular contractility, concomitant with a decrease in fibrotic tissue stiffness. These findings provide compelling evidence supporting IL-11 as a therapeutic target for myocardial fibrosis and highlight a novel delivery strategy for developing improved anti-fibrotic interventions.
科研通智能强力驱动
Strongly Powered by AbleSci AI